2025-12-22 - Analysis Report
Okay, let's break down the analysis of Johnson & Johnson (JNJ) based on the provided data.

**0) Report in English with Simple Numbers and Analysis**

**1) Comparison with S&P 500 (VOO)**

*   **Company Overview:** Johnson & Johnson is a global healthcare company that researches, develops, manufactures, and sells a broad range of products in the healthcare field.

*   **Performance Numbers:**
    *   JNJ Cumulative Return: 59.05%
    *   VOO Cumulative Return: 100.88%
    *   Divergence (JNJ - VOO): -41.83%
    *   Relative Divergence: 28.9

*   **Analysis:** JNJ has significantly underperformed the S&P 500 over the given period.  The -41.83% divergence indicates a substantial difference in cumulative returns. The Relative Divergence of 28.9 suggests that the current divergence is closer to the minimum historical divergence than the maximum.

**Alpha, Beta Analysis Table:**

| Year       | CAGR  | MDD   | Alpha | Beta | Cap(B) |
|------------|-------|-------|-------|------|--------|
| 2015-2017  | 26.0% | 66.8% | -2.0% | -0.1 | 336.6  |
| 2016-2018  | 14.0% | 10.7% | -1.0% | 0.1  | 310.9  |
| 2017-2019  | 20.0% | 71.5% | -2.0% | 0.4  | 351.4  |
| 2018-2020  | 19.0% | 79.2% | -4.0% | 0.4  | 379.2  |
| 2019-2021  | 33.0% | 79.2% | -14.0% | 0.5  | 412.2  |
| 2020-2022  | 8.0%  | 79.6% | 9.0%  | 0.4  | 425.6  |
| 2021-2023  | -19.0% | 79.6% | -20.0% | 0.3  | 377.6  |
| 2022-2024  | -32.0% | 79.6% | -53.0% | 0.3  | 348.4  |
| 2023-2025  | 30.0% | 79.6% | -35.0% | 0.1  | 497.2  |

*   **Analysis:**
    *   **CAGR (Compound Annual Growth Rate):** Fluctuates significantly, indicating periods of strong growth (e.g., 2019-2021) and significant decline (e.g., 2022-2024).
    *   **MDD (Maximum Drawdown):** Consistently high, particularly from 2017 onwards, suggesting considerable risk and volatility.
    *   **Alpha:**  Mostly negative, meaning JNJ has generally underperformed its expected return based on its risk (Beta). The 2020-2022 period is an exception, showing positive Alpha.
    *   **Beta:** Generally low (around 0.1 to 0.5), indicating that JNJ is less volatile than the overall market.
    *   **Cap(B) (Market Capitalization in Billions):** Showed growth until recently, followed by a decline, then a jump, suggesting changing investor sentiment and market conditions.

**2) Recent Stock Price Fluctuations**

*   Close Price: 206.37
*   Previous Close: 208.31
*   Change: -0.93
*   5-day SMA: 209.70
*   20-day SMA: 206.46
*   60-day SMA: 195.83

*   **Analysis:**
    *   The stock price is currently slightly down.
    *   The 5-day SMA is above the 20-day SMA, which is above the 60-day SMA. This could suggest a short-term upward trend, but the proximity of the 5-day and 20-day SMAs indicates that the trend is weak.

**3) RSI, PPO, and Divergence Indicators**

*   MRI: 0.7 (Medium Investment Recommended)
*   RSI: 53.23
*   PPO: -0.19
*   Hybrid Signal: cash_0%_Buy 90% of cash (1 shares - Safe - MRI:0.80)
*   Recent (20 days) relative divergence change: -5.1 (Short-term decline)
*   Expected Return: -59.0%

*   **Analysis:**
    *   **MRI:** A value of 0.7 suggests a medium level of investment risk.
    *   **RSI:** 53.23 indicates a neutral momentum, neither overbought nor oversold.
    *   **PPO:** -0.19 suggests a slight downward trend in price momentum.
    *   **Hybrid Signal:** Suggests buying, but with a high allocation to cash.
    *   **Recent Divergence Change:** The negative change indicates that JNJ's performance relative to the S&P 500 has worsened in the short term.
    *   **Expected Return:** A significant negative expected return (-59.0%) is a major concern, suggesting substantial underperformance compared to the S&P 500 in the long term.

**4) Recent News & Significant Events**

*   **Key Themes:**
    *   **Drug-Pricing Politics, Talc Verdicts, and FDA Wins:**  Highlights ongoing legal and regulatory challenges.
    *   **Stock Drops Despite Market Gains:** Suggests company-specific issues are impacting performance.
    *   **Shares Surging This Month:**  Indicates a period of positive momentum.
    *   **Investment Management Holdings:**  Shows institutional investment.
    *   **Stock Down 3% Today:** Reflects a recent negative price movement.
    *   **Key Levels and Resistance Levels:** Focuses on technical analysis for trading.

*   **Analysis:** The news is mixed. While there are positive mentions of institutional holdings and potential for FDA wins, the negative headlines regarding stock drops, legal issues, and underperformance are concerning.

**4-2) Analyst Opinions**

*   Consensus: Buy (Mean: 2.16)
*   Target Price (Avg/High/Low): 209.29 / 240.00 / 155.00

*   **Analysis:**  Analysts generally have a positive outlook on JNJ, with a "Buy" consensus. However, the wide range in target prices (155.00 to 240.00) suggests uncertainty. The average target price (209.29) is only slightly above the current price, indicating limited upside potential.

**5) Recent Earnings Analysis**

| 날짜        | EPS  | 매출       |
|-------------|------|------------|
| 2025-10-22 | 2.14 | 23.99 B$   |
| 2025-07-24 | 2.3  | 23.74 B$   |
| 2025-04-23 | 4.57 | 21.89 B$   |
| 2024-10-23 | 1.12 | 22.47 B$   |
| 2025-10-22 | 1.12 | 22.47 B$   |

*   **Analysis:**
    *   Revenue is fluctuating within a relatively narrow band.
    *   EPS (Earnings Per Share) is more volatile, with a notable spike in April 2025 and subsequent drops.

**6) Financial Information**

*Revenue and Profitability:*

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $23.99B   | 69.56%        |
| 2025-06-30   | $23.74B   | 67.87%        |
| 2025-03-31   | $21.89B   | 66.40%        |
| 2024-12-31   | $22.52B   | 68.35%        |
| 2024-09-30   | $22.47B   | 69.01%        |

*Capital and Profitability:*

| Quarter      | Equity    | ROE    |
|--------------|-----------|--------|
| 2025-09-30   | $79.28B   | 6.50%  |
| 2025-06-30   | $78.47B   | 7.06%  |
| 2025-03-31   | $78.11B   | 14.08% |
| 2024-12-31   | $71.49B   | 4.80%  |
| 2024-09-30   | $70.16B   | 3.84%  |

*   **Analysis:**
    *   **Revenue:**  Shows some fluctuation but is relatively stable.
    *   **Profit Margin:** Consistently high, indicating strong profitability.
    *   **Equity:** Increasing over time, showing growth in the company's asset base.
    *   **ROE (Return on Equity):**  Volatile. The high ROE in 2025-03-31 needs further investigation.

**7) Comprehensive Analysis**

**Summary:**

*   **Underperformance:** JNJ has significantly underperformed the S&P 500.
*   **Volatility:** The stock exhibits high maximum drawdowns and negative Alpha in most periods, suggesting significant risk.
*   **Mixed Signals:** Recent news and analyst opinions are mixed. While analysts have a positive outlook, news headlines point to legal challenges and stock drops.
*   **Financials:** Revenue and profit margins are strong, but ROE is volatile.
*   **Technical Indicators:**  The MRI suggests a medium investment risk, while the negative expected return is a major red flag.

**Conclusion:**

Based on this data, JNJ appears to be facing significant headwinds. The underperformance relative to the S&P 500, high volatility, and negative expected return raise concerns about its future prospects. While analysts maintain a "Buy" rating, potential investors should carefully consider the risks and negative trends highlighted in the analysis. The legal and regulatory challenges mentioned in the news headlines are likely contributing to the stock's underperformance. Further investigation is needed to understand the reasons behind the volatile ROE and the spike in EPS in April 2025.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.